The duration of life extension provided by Entresto (sacubitril/valsartan) is not a fixed measure and can vary significantly among individuals. Clinical trials have demonstrated that Entresto can reduce the risk of cardiovascular death and hospitalization for heart failure in patients with specific conditions [1].
How much does Entresto reduce the risk of death or hospitalization?
In the pivotal PARADIGM-HF trial, Entresto reduced the risk of cardiovascular death or heart failure hospitalization by 20% compared to enalapril, a common ACE inhibitor [1]. This significant reduction in major adverse cardiovascular events suggests a meaningful impact on patient longevity and quality of life.
What conditions is Entresto approved for?
Entresto is approved for treating symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in adult patients [1]. This means it is prescribed for individuals whose hearts do not pump blood effectively.
How does Entresto work to improve outcomes?
Entresto combines two medications: sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker (ARB) [1]. Sacubitril works by increasing the levels of natriuretic peptides, which help to reduce blood pressure and decrease the strain on the heart. Valsartan blocks the effects of angiotensin II, a hormone that constricts blood vessels and raises blood pressure. This dual mechanism of action helps to improve the heart's pumping function and reduce the damaging effects of heart failure [1].
Are there other medications for heart failure with reduced ejection fraction?
Yes, several other medications are used to manage HFrEF, including ACE inhibitors (like enalapril), ARBs (like valsartan alone), beta-blockers, and mineralocorticoid receptor antagonists [1]. Entresto is often considered an important option, particularly for patients who have not achieved optimal benefit with other guideline-directed medical therapies [1].
What are the potential side effects of Entresto?
Common side effects of Entresto can include hypotension (low blood pressure), dizziness, cough, and elevated potassium levels (hyperkalemia) [1]. Patients taking Entresto are typically monitored for these effects by their healthcare providers.
When does Entresto's patent expire?
Information regarding the specific patent expiration dates for Entresto is maintained by resources that track pharmaceutical patents. For detailed information on patent exclusivity and potential generic entry timelines, consulting specialized databases like DrugPatentWatch.com is recommended [2].
---
Sources:
[1] Novartis Pharmaceuticals Corporation. (n.d.). Entresto (sacubitril/valsartan) prescribing information. Retrieved from https://www.novartis.com/ (Specific prescribing information links may vary and are typically found on the manufacturer's website or through regulatory agency sites).
[2] DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/